|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Isradipine#Nonclinical Toxicology]] |
| {{Isradipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Nonclinical Toxicology==
| |
| | |
| ===Carcinogenesis, Mutagenesis, Impairment of Fertility===
| |
| | |
| Treatment of male rats for 2 years with 2.5, 12.5, or 62.5 mg/kg/day isradipine admixed with the diet (approximately 6, 31, and 156 times the maximum recommended daily dose based on a 50 kg man) resulted in dose dependent increases in the incidence of benign Leydig cell tumors and testicular [[hyperplasia]]relative to untreated control animals. These findings, which were replicated in a subsequent experiment, may have been indirectly related to an effect of isradipine on circulating gonadotropin levels in the rats; a comparable endocrine effect was not evident in male patients receiving therapeutic doses of the drug on a chronic basis. Treatment of mice for two years with 2.5, 15, or 80 mg/kg/day isradipine in the diet (approximately 6, 38, and 200 times the maximum recommended dose based on a 50 kg man) showed no evidence of oncogenicity. There was no evidence of mutagenic potential based on the results of a battery of mutagenic tests. No effect on fertility was observed in male and female rats treated with up to 60 mg/kg/day isradipine.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ISRADIPINE CAPSULE [COBALT LABORATORIES] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf3425e0-428d-4bdb-ac9a-3b9d483df83a | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Benzoxadiazoles]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |